Current Report Filing (8-k)
June 23 2021 - 06:05AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of Report (Date of earliest event reported): June 23,
2021
PROVECTUS
BIOPHARMACEUTICALS, INC.
(Exact
name of registrant as specified in charter)
Delaware |
|
001-36457 |
|
90-0031917 |
(State
or other jurisdiction |
|
(Commission |
|
(IRS
Employer |
of
incorporation) |
|
File
Number) |
|
Identification
No.) |
10025
Investment Drive, Suite 250, Knoxville,
Tennessee
37932
|
(Address
of Principal Executive Offices) (Zip Code) |
(866)
594-5999 |
(Registrant’s
Telephone Number, Including Area Code) |
N/A
(Former
Name or Former Address, if Changed Since Last Report.)
|
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General
Instruction A.2 below):
[ ] |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
|
|
[ ] |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
|
[ ] |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
|
[ ] |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act: None
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
|
|
|
|
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging
growth company [ ]
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
[ ]
Item
7.01. Regulation FD Disclosure.
During
its annual meeting of stockholders to be held on June 23, 2021,
Provectus Biopharmaceuticals, Inc. (the “Company”) will provide an
update about, among other things, the Company’s drug discovery and
development programs.
A
copy of the Company’s 2021 Annual Meeting of Stockholders
presentation slides is attached to this Current Report on Form 8-K
as Exhibit 99.1 and is incorporated herein by reference.
Pursuant
to the rules and regulations of the Securities and Exchange
Commission, the information in this Item 7.01 disclosure, including
Exhibit 99.1 and information set forth therein, is deemed to have
been furnished and shall not be deemed to be “filed” under the
Securities Exchange Act of 1934, as amended.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date:
June 23, 2021
|
PROVECTUS
BIOPHARMACEUTICALS, INC. |
|
|
|
By: |
/s/
Heather Raines |
|
|
Heather
Raines |
|
|
Chief
Financial Officer (Principal Financial Officer) |
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Apr 2022 to May 2022
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From May 2021 to May 2022